menu
    • menu
    [{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Arginine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Isotope Technologies Munich \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Not Applicable"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Grand Pharmaceutical Group Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2022","type":"Licensing Agreement","leadProduct":"Lutetium-177-edotreotide","moa":"SSTR2","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0.58999999999999997,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.58999999999999997,"dosageForm":"","sponsorNew":"Isotope Technologies Munich \/ Grand Pharmaceutical Group Limited","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Grand Pharmaceutical Group Limited"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Grand Pharmaceutical Group Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2021","type":"Licensing Agreement","leadProduct":"Lutetium-177-edotreotide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0.58999999999999997,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.58999999999999997,"dosageForm":"","sponsorNew":"Isotope Technologies Munich \/ Grand Pharmaceutical Group Limited","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Grand Pharmaceutical Group Limited"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Arginine","moa":"SSTR2","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Isotope Technologies Munich \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Not Applicable"},{"orgOrder":0,"company":"Isotope Technologies Munich","sponsor":"Indigenous Critical Infrastructure Fund Canada","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2022","type":"Financing","leadProduct":"Arginine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Isotope Technologies Munich","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Isotope Technologies Munich \/ Indigenous Critical Infrastructure Fund Canada","highestDevelopmentStatusID":"10","companyTruncated":"Isotope Technologies Munich \/ Indigenous Critical Infrastructure Fund Canada"},{"orgOrder":0,"company":"Mangoceuticals","sponsor":"Greater NY Chamber of Commerce","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Tadalafil","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Mangoceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mangoceuticals \/ Greater NY Chamber of Commerce","highestDevelopmentStatusID":"12","companyTruncated":"Mangoceuticals \/ Greater NY Chamber of Commerce"},{"orgOrder":0,"company":"Mangoceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Mangoceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mangoceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mangoceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Mangoceuticals","sponsor":"Boustead Securities","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Tadalafil","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Mangoceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mangoceuticals \/ Boustead Securities","highestDevelopmentStatusID":"12","companyTruncated":"Mangoceuticals \/ Boustead Securities"},{"orgOrder":0,"company":"Emifarma","sponsor":"Mangoceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Tadalafil","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Emifarma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Emifarma \/ Mangoceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Emifarma \/ Mangoceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals for L-Arginine

    Menu

    L-Arginine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Emifarma

                            Mexico arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Emifarma

                            Mexico arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tadalafil,Oxytocin,L-Arginine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved

                            Sponsor : Mangoceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Mangoceuticals' MangoRx Mexico Signs Agreement for Development Of ED Products

                            Details : Emifarma will be responsible for initial development & testing of the Company’s Mango ED products a combination of Tadalafil, Oxytocin, and L-Arginine intended for Mexican and Latin American markets.

                            Brand Name : Mango ED

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 12, 2024

                            Lead Product(s) : Tadalafil,Oxytocin,L-Arginine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved

                            Sponsor : Mangoceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Mangoceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Mangoceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tadalafil,Oxytocin,L-Arginine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved

                            Sponsor : Boustead Securities

                            Deal Size : $1.2 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Mangoceuticals, Inc. Announces Pricing of $1,200,000 Public Offering

                            Details : The Company intends to use the net proceeds to finance the marketing and operational expenses associated with the planned marketing of its Mango ED, a combination of Tadalafil, Oxytocin, and L-Arginine that have been traditionally used to treat sexual dy...

                            Brand Name : Mango ED

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 15, 2023

                            Lead Product(s) : Tadalafil,Oxytocin,L-Arginine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved

                            Sponsor : Boustead Securities

                            Deal Size : $1.2 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Mangoceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Mangoceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sildenafil Citrate,Oxytocin,L-Arginine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mangoceuticals Launches New Sildenafil Based Erectile Dysfunction Product with Signature Mango Flavor & Rapid ...

                            Details : Mango (sildenafil citrate) mango-flavored, rapid dissolve tablet is a Phosphodiesterase-5 inhibitor, which is being indicated for the treatment of erectile dysfunction.

                            Brand Name : Mango

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 16, 2023

                            Lead Product(s) : Sildenafil Citrate,Oxytocin,L-Arginine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Mangoceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Mangoceuticals

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tadalafil,Oxytocin,L-Arginine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved

                            Sponsor : Greater NY Chamber of Commerce

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Mangoceuticals Partners with Greater NY Chamber of Commerce for Mass Marketing & Sales of Flagship Mango Produ...

                            Details : The partnership aims bring its flagship product, Mango, a combination of Tadalafil, Oxytocin, and L-Arginine that have been traditionally used to treat sexual dysfunction, to New York.

                            Brand Name : Mango

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 09, 2023

                            Lead Product(s) : Tadalafil,Oxytocin,L-Arginine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved

                            Sponsor : Greater NY Chamber of Commerce

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Isotope Technologies Munich

                            Germany arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Isotope Technologies Munich

                            Germany arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : n.c.a. Lutetium-177-edotreotide,L-Arginine,Lysine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Indigenous Critical Infrastructure Fund Canada

                            Deal Size : $36.3 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            ITM Receives EUR 33 Million Equity Investment to Advance Precision Oncology Pipeline of Targeted Radiopharmace...

                            Details : The proceeds will be used for the finalization of the late-stage development of the lead candidate ITM-11 (n.c.a. 177Lu-edotreotide), a targeted radiopharmaceutical currently being evaluated in phase III for the treatment of gastroenteropancreatic neuroe...

                            Brand Name : ITM-11

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            March 22, 2022

                            Lead Product(s) : n.c.a. Lutetium-177-edotreotide,L-Arginine,Lysine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Indigenous Critical Infrastructure Fund Canada

                            Deal Size : $36.3 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Isotope Technologies Munich

                            Germany arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Isotope Technologies Munich

                            Germany arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : n.c.a. Lutetium-177-edotreotide,L-Arginine,Lysine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ITM Presents Design of Second Phase III Trial, COMPOSE, with Radiopharmaceutical ITM-11 for the Treatment of N...

                            Details : ITM-11, a targeted radionuclide therapy consisting of high-quality radioisotope, no-carrier-added lutetium-177 combined with somatostatin analog edotreotide is best standard of care for patients with neuroendocrine tumors.

                            Brand Name : ITM-11

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            March 09, 2022

                            Lead Product(s) : n.c.a. Lutetium-177-edotreotide,L-Arginine,Lysine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Isotope Technologies Munich

                            Germany arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Isotope Technologies Munich

                            Germany arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lutetium-177-edotreotide,L-Arginine,Lysine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Grand Pharmaceutical Group Limited

                            Deal Size : $588.4 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            ITM Receives Equity Investment of EUR 25 Million from Strategic Partner Grand Pharma

                            Details : The equity investment follows the licensing agreement between companies which provides GP with rights to develop, manufacture and commercialize ITM’s precision oncology radiopharmaceutical candidates, ITM-11 (n.c.a. 177Lu-edotreotide) and ITM-41 (n.c.a...

                            Brand Name : ITM-11

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            February 16, 2022

                            Lead Product(s) : Lutetium-177-edotreotide,L-Arginine,Lysine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Grand Pharmaceutical Group Limited

                            Deal Size : $588.4 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Isotope Technologies Munich

                            Germany arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Isotope Technologies Munich

                            Germany arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : n.c.a. Lutetium-177-edotreotide,L-Arginine,Lysine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ITM Presents Study Design of COMPOSE Phase III Trial with ITM-11 (n.c.a. 177Lu-edotreotide) for Treatment of N...

                            Details : ITM-11 (177Lu-edotreotide), a synthetic form of the peptide hormone somatostatin that targets neuroendocrine tumor-specific receptors demonstrated promising results in its trial for the treatment of hard-to-treat tumors.

                            Brand Name : ITM-11

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            January 19, 2022

                            Lead Product(s) : n.c.a. Lutetium-177-edotreotide,L-Arginine,Lysine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Isotope Technologies Munich

                            Germany arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Isotope Technologies Munich

                            Germany arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lutetium-177-edotreotide,L-Arginine,Lysine

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Grand Pharmaceutical Group Limited

                            Deal Size : $588.4 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            ITM and Grand Pharma Enter into a Commercialization Agreement for Targeted Radiopharmaceuticals in the Greater...

                            Details : Under the terms of the agreement, ITM grants GP an exclusive license for the ITM-11 (n.c.a. 177Lu-edotreotide) and ITM-41 (n.c.a. 177Lu-zoledronate), in the licensed territory and will support the supply of the pharmaceuticals needed for clinical and com...

                            Brand Name : ITM-11

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            December 27, 2021

                            Lead Product(s) : Lutetium-177-edotreotide,L-Arginine,Lysine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Grand Pharmaceutical Group Limited

                            Deal Size : $588.4 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth